Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $60.89

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $60.8889.

Several analysts recently issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Immunocore in a report on Friday. They issued an “overweight” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of Immunocore in a report on Monday, August 25th. They issued a “buy” rating and a $48.00 price target on the stock. Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 4th. Finally, Guggenheim assumed coverage on shares of Immunocore in a report on Thursday, September 18th. They issued a “neutral” rating on the stock.

Immunocore Trading Down 2.1%

NASDAQ IMCR opened at $32.38 on Friday. The company’s fifty day simple moving average is $33.87 and its 200-day simple moving average is $33.13. Immunocore has a 52 week low of $23.15 and a 52 week high of $39.33. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01. The stock has a market cap of $1.63 billion, a P/E ratio of -80.95 and a beta of 0.79.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The business had revenue of $130.65 million for the quarter, compared to analysts’ expectations of $122.96 million. During the same period in the previous year, the company posted ($0.23) earnings per share. The business’s revenue for the quarter was up 30.0% compared to the same quarter last year. Equities research analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling at Immunocore

In other Immunocore news, insider David M. Berman sold 22,532 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 10.40% of the company’s stock.

Institutional Trading of Immunocore

A number of institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the period. Virtus Investment Advisers LLC raised its holdings in shares of Immunocore by 5.3% during the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company’s stock worth $391,000 after purchasing an additional 625 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Immunocore by 1.1% during the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company’s stock worth $1,996,000 after purchasing an additional 735 shares during the period. Orion Porfolio Solutions LLC raised its holdings in shares of Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after purchasing an additional 1,031 shares during the period. Finally, Assetmark Inc. grew its position in shares of Immunocore by 3.7% during the second quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock worth $1,097,000 after acquiring an additional 1,248 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.